🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

25 results for “Ipsen” Clear

  1. Abraxane 5 mg/ml powder for dispersion for infusion., Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion, Fluorouracil Accord 50 mg/ml šķīdums injekcijām vai infūzijām, CALCIUM FOLINATE , GEMCITABINE ACCORD 100 mg/ml, solution à diluer pour perfusion, Oxaliplatin Accord 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Ipsen Pharma

    Metastatic Pancreatic Adenocarcinoma

    phase 3 small molecule active

    1 trial

  2. Cabozantinib Ipsen 60 mg film-coated tablets, XL092, XL092, XL092, BELZUTIFAN, Cabozantinib Ipsen 20 mg film-coated tablets, XL092

    Merck Sharp and Dohme

    Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  3. Dysport Placebo Solution for injection, Botulinum Toxin Type A 500 units Powder for solution for injection, Botulinum Toxin Type A 300 units Powder for solution for injection

    Ipsen Pharma

    Chronic migraine

    phase 3 small molecule active

    1 trial

  4. Dysport Placebo Solution for injection, Botulinum Toxin Type A 300 units Powder for solution for injection, Botulinum Toxin Type A 500 units Powder for solution for injection

    Ipsen Pharma

    Episodic Migraine

    phase 3 small molecule active

    1 trial

  5. Excipients without active substance - Lyophilised powder for solution for injection - Intramuscolar Use

    Ipsen Pharma

    Treatment of moderate to severe glabellar lines

    phase 3 small molecule active

    1 trial

  6. KAYFANDA 200 microgram hard capsules, KAYFANDA 400 microgram hard capsules, KAYFANDA 600 microgram hard capsules, KAYFANDA 1 200 microgram hard capsules

    Ipsen Pharma

    Alagille Syndrome

    phase 3 small molecule active

    1 trial

  7. elafibranor, Elafibranor Placebo

    Ipsen Pharma

    Primary Biliary Cholangitis (PBC)

    phase 3 small molecule active

    1 trial

  8. elafibranor, Placebo

    Ipsen Pharma

    Primary Biliary Cholangitis

    phase 3 small molecule active

    1 trial

  9. elafibranor, Placebo tablet

    Ipsen Pharma

    Primary Biliary Cholangitis

    phase 3 small molecule active

    1 trial

  10. An Open-label, Phase I/II First-in-Human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumor Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants with Advanced Solid Tumors

    Ipsen Pharma

    Pancreatic Ductal Adenocarcinoma, Melanoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Solid tumors

    phase 2 other active

    1 trial

  11. CABOMETYX 60 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets

    Ipsen Pharma

    Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with a Clear-Cell Component Who Progressed After 1st Line Treatment with Checkpoint Inhibitors

    phase 2 small molecule active

    1 trial

  12. Cabozantinib Ipsen 20 mg film-coated tablets

    Disc Medicine

    Renal cell carcinom

    phase 2 small molecule active

    1 trial

  13. IPN01195, IPN01195

    Ipsen Pharma

    Advanced Solid Tumour

    phase 2 small molecule active

    1 trial

  14. IPN01203

    Ipsen Pharma

    Advanced Solid Tumor, Metastatic Solid Tumor

    phase 2 small molecule active

    1 trial

  15. IPN10200 placebo, DYSPORT 300 UNITES SPEYWOOD, poudre pour solution injectable, IPN10200

    Ipsen Pharma

    Treatment of Moderate to Severe Upper Facial Lines

    phase 2 small molecule active

    1 trial

  16. IPN10200 placebo, Powder for solution for injection, DYSPORT 500 UNITES SPEYWOOD, poudre pour solution injectable

    Ipsen Pharma

    Upper limb spasticity after stroke or traumatic brain injury

    phase 2 small molecule active

    1 trial

  17. IPN10200, IPN10200 placebo

    Ipsen Pharma

    Episodic Migraine Chronic Migraine

    phase 2 small molecule active

    1 trial

  18. IPN60300

    Ipsen Pharma

    Advanced or metastatic solid tumours

    phase 2 small molecule active

    1 trial

  19. Placebo capsule

    Ipsen Pharma

    Fibrodysplasia Ossificans Progressiva

    phase 2 small molecule active

    1 trial

  20. Placebo of IPN10200, IPN10200

    Ipsen Pharma

    Cervical Dystonia

    phase 2 small molecule active

    1 trial

  21. elafibranor, Placebo of Elafibranor, elafibranor

    Ipsen Pharma

    Primary Sclerosing Cholangitis

    phase 2 small molecule active

    1 trial

  22. A Mass Balance Study of [14C]-IPN60250 in Healthy Adult Participants

    Ipsen Pharma

    Primary sclerosing cholangitis (PSC)

    phase 1 other active

    1 trial

  23. A study to assess the effect of gemfibrozil, itraconazole and phenytoin on levels of IPN60250 in the blood of healthy adult participant.

    Ipsen Pharma

    Not applicable

    phase 1 other active

    1 trial

  24. A study to compare Onivyde manufactured at two different production sites in adult participants with advanced cancer in the pancreas

    Ipsen Pharma

    Metastatic Pancreatic Adenocarcinoma

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources